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ABSTRACT
While carcinoma of the prostate is the second most common cause of cancer 
death in the US, current methods and markers used to predict prostate cancer (PCa) 
outcome are inadequate. This study was aimed at understanding the genome-wide 
binding and regulatory role of the DAXX transcriptional repressor, recently implicated 
in PCa. ChIP-Seq analysis of genome-wide distribution of DAXX in PC3 cells revealed 
over 59,000 DAXX binding sites, found at regulatory enhancers and promoters. ChIP-
Seq analysis of DNA methyltransferase 1 (DNMT1), which is a key epigenetic partner 
for DAXX repression, revealed that DNMT1 binding was restricted to a small number of 
DAXX sites. DNMT1 and DAXX bound close to transcriptional activator motifs. DNMT1 
sites were found to be dependent on DAXX for recruitment by analyzing DNMT1 ChIP-
Seq following DAXX knockdown (K/D), corroborating previous findings that DAXX 
recruits DNMT1 to repress its target genes. Massively parallel RNA sequencing (RNA-
Seq) was used to compare the transcriptomes of WT and DAXX K/D PC3 cells. Genes 
induced by DAXX K/D included those involved in autophagy, and DAXX ChIP-Seq peaks 
were found close to the transcription start sites (TSS) of autophagy genes, implying 
they are more likely to be regulated by DAXX. In conclusion, DAXX binds active 
regulatory elements and co-localizes with DNMT1 in the prostate cancer genome. 
Given DAXX’s putative regulatory role in autophagy, future studies may consider DAXX 
as a candidate marker and therapeutic target for prostate cancer.
INTRODUCTION
According to the American Cancer Society, Cancer 
Facts & Figures, 2014, among men, carcinoma of the 
prostate is the second most common cause of cancer death 
in the US, with 29,480 deaths per year. Once PCa has 
metastasized, controlling it is often unsuccessful. Current 
methods and markers used to predict PCa outcome are 
inadequate. Discovering a new PCa marker that promises 
to improve prognostication beyond what is achieved with 
other reported biomarkers becomes of utmost importance.
Many studies have shown that cell death-modulating 
protein DAXX functions as a transcriptional repressor [1-
4]. DAXX associates with RelB, a transcription factor of 
the NF-κB family that directly controls the expression 
of numerous apoptosis- and autophagy-relevant genes, 
including tumor suppressor protein kinases DAPK1/3 
[1;2]. A positive connection between DAPK1 and 
autophagy/tumor suppression has been established [5-8]. 
In mouse embryo fibroblasts (MEFs) [2], as well as in 
the PCa cell lines [unpublished data], DAXX represses 
expression of these genes via mechanisms that include 
its binding to DNA methyl transferases (DNMTases) 
and hypermethylation of the promoter regions of the 
corresponding genes [2]. DAXX also recruits DNMTases 
to viral DNA so as to initiate its epigenetic repression 
[4]. A number of publications have reproducibly shown 
that DAXX interacts directly with DNMTs and employs 
DNA methylation as a major mechanism of repression 
[2-4]. DAXX is also known to repress through additional 
mechanisms, including recruitment of histone deacetylases 
(HDACs) to target promoters [2], and histone H3.3 
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association/regulation [9]. Conversely, DAPK1, has 
been shown to be the target of repression in a number 
of cancers, including AML [10], breast cancer [11], and 
PCa [Submitted]. Through its ability to repress tumor 
suppressors, DAXX would be expected to induce tumor 
growth or survival. It was indeed found DAXX promotes 
the in vivo tumorigenicity of two human PCa cell lines in 
a subcutaneous tumor xenograft model via suppression of 
autophagy [Submitted]. 
Defects in cell death mechanisms represent one 
of the six identified cardinal features of cancer [12], and 
are commonly associated with progression of tumors to 
refractory, chemoresistant disease [13]. Several anti-
apoptotic genes have been discovered that are over-
expressed in hormone-refractory prostate cancers [14]. 
A number of lines of evidence indicate that in a cancer 
context, like in development (Daxx-null genotype is an 
embryonic lethal condition in which the embryos die 
by age E9.5 [15], due to global apoptosis), DAXX may 
have a pro-survival role. In prostate tissues, DAXX 
staining intensity is stronger in areas surrounding tumor 
glands compared to areas surrounding normal glands 
[16]. Moreover, strong positive DAXX staining has been 
observed in PCa tissues, compared to benign prostatic 
hyperplasia (BPH) tissues, suggesting that DAXX is 
overexpressed in PCa [17]. In prostate cells, DAXX 
levels are increased in various PCa cell lines, relative 
to nontumorigenic human prostatic epithelial lines 
[17;Submitted]. Conversely, in cells and tissues, DAPK1 
and DAPK3 are downregulated in cancer contexts 
[18;Submitted]. An inverse correlation has been found 
between DAXX and DAPK1/3 mRNA expression in a 
diverse collection of human tumor cell lines and tumor 
specimens [Submitted], suggesting that DAXX’s role 
as a transcriptional repressor of DAPK1/3 [2] is broadly 
relevant to tumor biology and is not restricted to PCa. 
Nevertheless, where DAXX binds in the PCa genome, 
or what effect it has on the expression of other genes, 
has not been determined. We performed ChIP-Seq and 
RNA-Seq to address the above questions. Our results are 
in agreement with the deposited data in the Oncomine 
database [Submitted], and establish that DAXX-DNMT1 
association is important in PCa progression. 
In conclusion, DAXX can serve as an improved 
marker and attractive therapeutic target in PCa.
RESULTS
DNMT1 peaks overlap with, and are dependent 
on, DAXX
DAXX is a multifaceted protein with a key role 
in transcriptional repression [1-4], but its genome-
wide distribution in PCa via ChIP-Seq has never been 
investigated. To determine DAXX binding sites in the PCa 
genome, specifically in the PC3 cell line (derived from 
bone metastasis of a human PCa case [19]), we generated 
a stable shRNA knockdown (K/D) PC3 cell line and a 
control shRNA counterpart [Submitted], and performed 
a ChIP-Seq study. ChIP-Seq for DAXX was successful, 
as the strength of the signal in the experimental sample 
(Figure 1A, top panel) was high compared to the signal 
from the negative control, the input (Figure 1A, bottom 
panel). DAXX co-localized with H3K4 and H3K27 histone 
marks and other factors (RNA Pol II, CTCF) in PC3 cells 
(Figure 1A). DAXX was found largely at promoter-distal 
regions, and not on coding regions (Figure 1B). The 
~60,000 DAXX peaks found in WT PC3 cells localized 
to promoters, enhancers, and insulators (Figure 1C). 
DAXX recruitment to enhancers was at the nucleosome-
free region, alongside other transcription factors and co-
factors (Figure 1D). De novo motif enrichment showed 
that DAXX strongly bound to transcriptional activator 
motifs (Figure 1E), although possibly indirectly to DNA, 
and likely as part of a complex, due to its lack of DNA 
binding domains [2]. The motifs included those for ETS 
transcription factor family, previously shown to interact 
with DAXX [20]. DAXX bound to a large fraction (34%) 
of all enhancers in PC3 cells (Figure 1F), and it co-bound 
with CTCF to nearly 5,000 sites (Figure 1G), consistent 
with the motif analysis (Figure 1E). Importantly, ChIP-
Seq for DNMT1 showed that DNMT1 colocalized with 
DAXX and was DAXX-dependent (Figure 2A, top three 
panels). In contrast, the negative control (input, Figure 2A, 
bottom panel), did not produce specific signals. DNMT1 
peaks, similar to DAXX, were found largely at promoter-
distal regions (Figure 2B). A large fraction (52%) of 
DNMT1 peaks were also co-bound by DAXX (Figure 
2C), suggesting that DAXX may be required for DNMT1 
recruitment. De novo motif analysis of DNMT1 peaks 
found that AP-1 and an unknown motif were enriched at 
DNMT1 peaks (Figure 2D). Many of the DNMT1 peaks 
were lost after DAXX knockdown (2,237 DNMT1 peaks 
in WT (Figure 2C) vs. 600 DNMT1 peaks in DAXX K/D 
(Figure 2E)), indicating that DNMT1 recruitment is 
almost entirely dependent on DAXX further corroborating 
previous findings that DAXX recruits DNMT1 to repress 
its target genes [2].
Autophagy genes map close to DAXX ChIP-Seq 
peaks
Next, the distribution of gene transcription start 
sites (TSS) nearest to the DAXX ChIP-Seq peaks was 
analyzed.  Regulated gene TSS are normally found closer 
to the ChIP-Seq peaks than non-regulated peaks [21]. In 
one study [21], 28% of TSS were located within 5 kb of 
ChIP-Seq peaks. Autophagy genes, including DAPK3 
and ULK1, which were previously shown to be DAXX 
repression targets [Submitted], were found to be closer 
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Figure 1: DAXX ChIP-Seq reveals that DAXX binds active regulatory elements. A. ChIP-Seq binding profile of DAXX 
in PC3 cells at the NRP1 locus. Previously published (accessed through GEO database repository - NCBI) ChIP-Seq data for chromatin 
modification H3K4me3, H3K4me1, H3K27ac, H3K27me3, and factors RNA polymerase II and CTCF are shown. B. Annotation of 
59,778 DAXX ChIP-Seq peaks relative to RefSeq transcript annotations. C. Heatmap depicting the ChIP-Seq read density within ±3 kb 
from DAXX peaks for DAXX and several chromatin marks. Regions were hierarchically clustered to segregate regions with different 
enrichment patterns. D. Enrichment of epigenetic ChIP-Seq experiments relative to promoter-distal DAXX ChIP-Seq peaks. E. Results of 
de novo motif enrichment on DAXX ChIP-Seq peaks using HOMER. F. Overlap between promoter-distal DAXX and putative enhancers 
(promoter-distal H3K27ac peaks). Significance of overlap p-value < 10-100 (binomial test, relative to random genomic distribution). G. 
Overlap between DAXX and CTCF peaks. Significance of overlap p-value < 10-100 (binomial test, relative to random genomic distribution).
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to DAXX ChIP-Seq peaks than all other genes combined 
(Figure 3), implying that they are very likely to be 
regulated by DAXX (with the difference being highly 
significant: p < 10-7).
DNMT1 levels are reduced in genes upregulated 
in DAXX K/D cells compared to WT cells
To identify the genes induced and repressed in WT 
and DAXX K/D cells, RNA-Seq was performed. High 
quality RNA was first isolated from duplicate samples 
from each cell line (Figure 4A). RNA-Seq analysis showed 
that 2,716 genes were increased and 2,329 were decreased 
in DAXX K/D cells compared to control (Figure 4B). 
Genes induced by DAXX K/D included those involved 
in autophagy (subsequent figures). Next, the ChIP-Seq 
and RNA-Seq data were co-analyzed. DNMT1 levels at 
DAXX ChIP-Seq peaks within 10 kbp of the TSS of genes 
upregulated by shDAXX were determined (Figure 4C). 
Genes upregulated in DAXX K/D cells displayed lower 
DNMT1 levels than those in WT cells, indicating that 
DNMT1 is employed by DAXX in WT cells to repress 
these genes. 
RNA-Seq reveals that DAXX is an autophagy 
modulator
Based on ChIP-Seq findings (Figure 3), we focused 
our analysis on the relationship between DAXX and 
autophagy genes. To that end, RNA-Seq was utilized, 
Figure 2: DAXX and DNMT1 ChIP-Seq’s reveal that DAXX peaks overlap with DNMT1 peaks. A. ChIP-Seq binding 
profile of DAXX, DNMT1, and epigenetic markers in PC3 cells at the ETV1 locus. DNMT1 binding is shown for both WT and DAXX 
K/D conditions B. Annotation of 2,237 DNMT1 ChIP-Seq peaks relative to RefSeq transcript annotations. C. Overlap between DAXX 
and DNMT1 peaks. Significance of overlap p-value < 10-100 (binomial test, relative to random genomic distribution). D. Results of de novo 
motif enrichment on DAXX ChIP-Seq peaks using HOMER. E. Overlap between DNMT1 peaks found in PC3 WT cells and PC3 DAXX 
K/D cells. 
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using duplicate samples per cell line (WT and DAXX 
K/D). DAXX expression correlated inversely with 
expression of positive regulators of autophagy, including 
DAPK1, DAPK3, ATG8, ATG18, ATG101, LC20, ATG3, 
ATG4, Beclin1, ATG7 (Figure 5), and Deptor (not shown), 
whereas it correlated positively with expression of negative 
regulators of autophagy, mTOR and Raptor (Figure 6A 
and 6B). DAXX may increase mTOR/mTORC1/Raptor 
activity by suppressing ULK1 [Submitted], which, through 
a negative feedback loop, phosphorylates and inhibits 
Raptor and subsequently inhibits mTORC1 signaling [22]. 
Through an as of yet unidentified mechanism, DAXX 
may also affect mTOR and Raptor levels, in addition 
to their activity. As expected, DAXX RNA expression 
levels were decreased (65%) in DAXX K/D cells (Figure 
5, 6A, and 6B). Genome browser examples (Figure 6A) 
and a condensed heat map from RNA-Seq experiments 
(Figure 6B) show an inverse correlation between DAXX 
and DAPK3 and a linear correlation between DAXX and 
mTOR. Therefore, in conjunction with previous findings 
[Submitted], DAXX appears to repress autophagy in PCa. 
Of note, an effect on ULK1, another DAXX repression 
target [Submitted], was not observed via RNA-Seq. To 
validate RNA-Seq data on ULK1, we performed Q-PCR 
using the same RNA that was used for RNA-SEQ. Q-PCR 
showed that ULK1 mRNA levels were increased 3-7-
fold in DAXX K/D samples, using the cyclophilin (CPH) 
internal control gene for normalization (Figure 6C). 
Although there was variability between replicates, it did 
not amount to significant difference (Figure 6C). Use of an 
alternative internal control, (GAPDH), showed a similar 
fold increase (not shown). The reason for the difference in 
the fold change in ULK1 RNA levels observed in WT and 
DAXX K/D PC3 cells between the RNA-Seq and Q-PCR 
analyses is unclear, but we believe that the Q-PCR result 
is reliable based on the replicates we obtained. 
DISCUSSION
In the current study, utilizing ChIP-Seq, we 
investigated the genome-wide binding of the DAXX 
transcriptional repressor and its epigenetic partner 
DNMT1 in the PC3 PCa cell line, and found that DNMT1 
enrichment is dependent on DAXX. Importantly, ChIP-
Seq showed that autophagy genes mapped closer to DAXX 
peaks than all other genes combined, indicating that they 
are likely to be regulated by DAXX. Additionally, using 
RNA-Seq, we determined changes in gene expression 
levels between the wild-type (WT) and DAXX knock-down 
(K/D) PC3 cells. Genes increased by DAXX K/D included 
those involved in autophagy. Related to autophagy genes, 
ChIP-Seq and RNA-Seq data showed significant overlap. 
Specifically, among autophagy genes, the presence of 
DAXX was inversely correlated with the expression 
of positive regulators of autophagy - DAPK1, DAPK3, 
ATG8, ATG18, ATG101, LC20, ATG3, ATG4, Beclin1, 
ATG7, and Deptor, whereas it correlated positively with 
negative regulators of autophagy – mTOR and Raptor. 
The current study provides further clarification on 
the role of the DAXX transcriptional repressor in prostate 
tumorigenesis and progression. In many types of cancer, 
including PCa [23], tumor suppressors, such as DAPK1 
and DAPK3, are downregulated, a process that facilitates 
cancer metastasis. One of the proteins that represses the 
DAPK1 and DAPK3 genes is DAXX [2], and our working 
hypothesis is that suppression of DAPKs by DAXX results 
in increased prostate tumorigenesis and progression 
[Submitted]. The goal is to restore the activity of DAPKs 
in patients with advanced prostate cancer by inhibiting 
production of DAXX, for example via tissue-specific 
shRNA delivery, which has already shown potential 
in cancer therapy [24]. The results of this project may 
guide current therapeutic efforts to employ tissue-specific 
Figure 3: Autophagy genes map closer to DAXX ChIP-
Seq peaks than expected. Distribution of gene transcription 
start site (TSS) to the nearest DAXX ChIP-Seq peak was 
analyzed using HOMER. Regulated gene TSS are normally 
found closer to the ChIP-Seq peaks than non-regulated peaks. 
Autophagy genes (Tampaku.org/autophagy/list/GeneList) were 
found to be closer to DAXX ChIP-Seq peaks than all other genes 
combined, implying that they are more likely to be regulated by 
DAXX (with the difference being very significant: p < 10-7). The 
Y-axis represents distance from TSS to the nearest DAXX ChIP-
Seq peak in bp (ULK1: 1,464 bp; DAPK3: 2,401 bp).
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shRNA delivery in the treatment of metastatic PCa. This 
approach would inactivate the DAXX pathway for tumor 
promotion, and consequently restore the activity of the 
DAPK1 and DAPK3 tumor suppressors. In combination 
with this approach, inhibitors of DNA methylation and/
or histone deacetylases are expected to relieve repression 
of DAPK tumor suppressors, whose epigenetic silencing 
has emerged as a recurring theme from our work and 
throughout the literature. Restoring the activity of 
endogenous tumor suppressors is an attractive strategy 
for controlling malignancy, because it taps into natural 
pathways for self-defense against cancer. 
Our study represents the first to determine DAXX 
location in the PCa genome, as well as its correlation 
with the expression of PCa genes. We utilized the PCa 
cell line PC3, derived from a PCa bone metastasis [19]. 
An important finding was that DNMT1 ChIP-Seq peaks 
overlapped with DAXX peaks (Figure 2), and that 
DNMT1 was dependent on DAXX for recruitment to 
specific sites in the PCa genome. The DNMT1 number 
of ChIP-Seq peaks was considerably lower than that of 
DAXX, but in agreement with other reported ChIP-Seq 
studies involving DNMT1 [25].
Corroborating our recent findings [Submitted], 
through ChIP-Seq studies, DAXX was found to be 
strongly bound to its repression targets - DAPK3 and 
Figure 4: Genes whose expression is increased by DAXX knock down in PC3 cells show low levels of DNMT1 association. 
A. Total RNA was isolated from PC3 cells as described under Methods. High quality RNA was obtained, as evidenced by high RINs (RNA 
Integrity Numbers). The first two lanes represent WT samples, whereas lanes 3 and 4 represent DAXX K/D samples. B. Massively parallel 
RNA sequencing (RNA-Seq) was used to investigate in an unbiased fashion the expression of different genes, comparing the WT and 
DAXX K/D expression patterns in PC3 cells, using duplicate samples described in A.. RNA-Seq reads were aligned to the human genome 
using STAR. Gene expression was determined using HOMER. 2,716 genes were found to be induced and 2,329 repressed by DAXX K/D. 
Genes induced by DAXX K/D included those involved in autophagy. C. DNMT1 levels at DAXX ChIP-Seq peaks within 10kb of the TSS 
of genes upregulated by shDAXX are shown. Genes upregulated in DAXX K/D cells have lower DNMT1 levels than those in WT cells, 
indicating that DNMT1 is employed by DAXX in WT cells to repress these genes. 
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ULK1 – although DNMT1 was not found to have the same 
binding affinity for the promoters of these genes (10 kbp 
promoter length was examined). It is possible that DAXX 
employs several mechanisms to repress its targets, besides 
DNA methylation through DNMT1.
Also reinforcing our recent observations 
[Submitted], both ChIP- and RNA-Seq revealed that 
DAXX represses positive modulators of autophagy. 
DAXX expression inversely correlated with DAPK3 
(Figure 5, 6A, 6B: RNA-Seq), and ULK1 (Figure 6C: 
Q-PCR).
Oncomine analyses [Submitted] have shown a 
significant correlation between elevated DAXX expression 
and PCa development and progression/metastasis. Larger 
scale analyses will be needed to correlate expression 
of DAXX with pathological stage and survival. Future 
studies will also include immunohistochemistry analyses 
to confirm the bioinformatics/gene expression analyses. 
In addition to DAXX, immunohistochemistry studies 
will include DAPK1 and DAPK3 so as to establish a 
relationship between DAXX and the DAPK1/3 tumor 
suppressors. The correlations between DAXX and 
DAPK1/3 expression will be based on the tumor grade, 
stage, and disease metastasis. This study design will 
establish whether (1) DAXX can serve as a marker for 
early tumor growth or later advanced/metastatic PCa, and 
(2) high DAXX expression associates with indolent versus 
lethal PCa. 
In conclusion, bound DAXX co-localizes with 
bound DNMT1 in the prostate cancer genome. DAXX 
represses autophagy gene expression, presumably also 
because of its ability to recruit DNMT1, among other 
mechanisms. Autophagy acts as a tumor suppressor 
mechanism in PCa [Submitted]. We can envision that 
DAXX can serve as a precise prognostic marker in PCa 
and that tissue-specific shRNA delivery targeted against 
DAXX can be employed in the treatment of metastatic 
prostate cancer in patients, in particular if we discover, 
through additional studies, that DAXX is a marker for 
lethal PCa in humans. Improved knowledge of DAXX 
and its mechanisms will be helpful for identifying those 
patients for whom tissue-specific shRNA delivery will be 
Figure 5: DAXX expression is inversely correlated with the expression of positive regulators of autophagy. Using RNA-
Seq as described in Figure 4, among autophagy genes, DAXX expression was inversely correlated with expression of positive regulators of 
autophagy, including DAPK1, DAPK3, ATG8, ATG18, ATG101, LC20, ATG3, ATG4, Beclin1, ATG7, and Deptor (not shown), whereas it 
was linearly correlated with negative regulators of autophagy mTOR and Raptor (Figure 6). Duplicate samples were used per cell line. The 
graphs were prepared by determining gene expression using HOMER, and then plotted using Excel. 
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beneficial, thus ensuring that therapeutic intervention is 
appropriately tailored to each patient’s disease.
MATERIALS AND METHODS
Cell culture and recombinant lentivirus 
transduction 
The human prostate cancer cell line PC3, which 
was obtained from Scott Crist (Purdue University), was 
maintained in Roswell Park Memorial Institute-1640 
(RPMI-1640) medium, containing 10% fetal bovine 
serum, FBS (HyClone), and 1% penicillin/streptomycin 
plus L-glutamine. For the generation of a stable DAXX 
knock-down (K/D) PC3 line, recombinant lentiviruses 
targeting DAXX (constructed in the lentiviral backbone 
vector pLKO.1-puro) were purchased from Sigma 
(Clone ID: NM_001350.x-2410s1c1; Accession Number: 
NM_001350.3; Region: 3UTR). A non-specific control 
virus was also purchased (SHC002V: MISSION® Non-
Target shRNA Control Transduction Particles). 
Chromatin Immunoprecipitation (ChIP), Deep 
Sequencing (ChIP-Seq), and RNA Sequencing 
(RNA-Seq)
ChIP was performed using the Active Motif’s ChIP-
IT High Sensitivity kit (cat # 53040), starting with the 
control (WT or non-specific shRNA) and DAXX K/D 
PC3 cells. The manufacturer’s protocol was followed. 
The following goat polyclonal antibodies from Santa 
Figure 6: RNA-Seq reveals a connection between DAXX and autophagy regulators. Genome browser examples A. and a 
condensed heat map from RNA-Seq experiments B. show an inverse correlation between DAXX and DAPK3 and a linear correlation 
between DAXX and mTOR. Representative values are plotted in Figure 5. Read densities were visualized by preparing normalized BigWig 
files using HOMER and uploading them to the UCSC Genome Browser A., as described under Methods. Visualization of gene expression 
values as heatmaps B. was performed using Java TreeView. Duplicate samples were used per cell line. C. Q-PCR analysis was performed 
using cDNA samples as described under Materials and Methods to determine ULK1 mRNA levels in WT and DAXX K/D cells, and 
compare them to RNA-Seq results. DAXX K/D cells show increased levels of ULK1 mRNA compared to WT cells. The variability between 
replicates was not statistically significant.
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Cruz Biotechnology Inc. were used for ChIP: anti-DAXX 
(sc-7001) and anti-DNMT1 (sc-10219). A two-step cross-
linking procedure (protein-protein & DNA-protein) 
preceded ChIP as described [26], using disuccinimidyl 
glutarate (DSG) for protein-protein cross-linking (Thermo 
Scientific, cat # 20593). For ChIP, anti-DAXX or anti-
DNMT1 antibodies were used to collect chromatin bound 
to the respective antibody, and was followed by deep 
sequencing (ChIP-Seq) using an Illumina HiSeq 2500 
system. Non-immunoprecipitated (input) chromatin, 
subjected to the same treatment, served as a control. 
Massively parallel RNA sequencing (RNA-Seq) was used 
to investigate in an unbiased fashion the expression of 
different genes, comparing the control and DAXX K/D 
expression patterns in PC3 cells (duplicate samples). 
Total RNA was first isolated using NucleoSpin RNA kit 
(Clontech, cat # 740955). The RNA integrity number 
(RIN) was determined using The Agilent RNA ScreenTape 
assay (Agilent 2200 TapeStation, Salk Institute’s Next 
Generation Sequencing core), and high quality RNA was 
used for RNA-Seq. The RNA-Seq libraries were prepared 
using Illumina TruSeq RNA v2 non-stranded sample prep 
kits and sequenced on an Illumina HiSeq 2500 according 
to the manufacturer’s instructions. Genomic data analysis 
and visualization of ChIP-Seq and RNA-Seq analyses 
were performed as described below.
Genomic data analysis and visualization
ChIP-Seq Analysis
ChIP-Seq sequencing reads were mapped to the 
human genome (GRCh37/hg19) using Bowtie2 with 
default parameters (v2.1.0, [27]). Only reads that mapped 
to a single unique location were considered for further 
analysis. Genome browser BedGraph tracks and read 
density histograms were generated using HOMER [28]. 
Peak finding and annotation to the nearest RefSeq gene 
promoter was performed using HOMER (findPeaks 
program using the “-style factor” option). De novo motif 
discovery was also carried out using HOMER.
RNA-Seq Analysis
RNA-Seq reads were aligned to the human genome 
(GRCh37/hg19) using STAR with default parameters 
(v2.1.4a, [29]). Only reads that aligned to a single, unique 
location where kept for further analysis. Read densities 
were visualized by preparing normalized BigWig files 
using HOMER and uploading them to the UCSC Genome 
Browser (http://genome.ucsc.edu/). Gene expression was 
determined by identifying reads on the appropriate strand 
overlapping exons defined by RefSeq using HOMER. 
Differentially expressed genes were then identified using 
EdgeR [30]. Functional Enrichment with Gene Ontology 
was performed using DAVID [31]. Visualization of gene 
expression values as heatmaps was performed using Java 
TreeView [32].
Both ChIP-Seq and RNA-Seq analyses were 
performed using Salk Institute’s Next Generation 
Sequencing core facility.
Q-PCR analysis
PC3 and PC3 DAXX K/D cells were processed 
using Power SYBR Green Cells-to-Ct Kit (Ambion, Cat 
# 4402953) to lyse cells, generate cDNA, and perform 
Q-PCR per the manufacturer’s instructions. Applied 
Biosystems 7900HT Q-PCR instrument was used to 
amplify the samples, and the analysis was performed using 
SDSv2.4 software (Life Technologies). All statistical 
analyses were performed using GraphPad Prism 5. The 
sequences of the ULK1 and control (GAPDH & CPH) 
Q-PCR primers are as follows:
ULK1 forward primer: 5’- CAA GAG CAC ACG 
GAG ATC CTG C - 3’;
ULK1 reverse primer: 5’- CCC CAT TCT CGG 
CTC AGC AGG - 3’;
GAPDH forward primer: 5’ - ACA TCA AGA AGG 
TGG TGA AGC AGG - 3’;
GAPDH reverse primer: 5’ - ACA AAG TGG TCG 
TTG AGG GCA ATG - 3’;
CPH forward primer: 5’ - GAC CCA ACA CAA 
ATG GTT C - 3’;
CPH reverse primer: 5’ - AGT CAG CAA TGG 
TGA TCT TC - 3’.
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